A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors

Naing, A; Gainor, JF; Gelderblom, H; Forde, PM; Butler, MO; Lin, CC; Sharma, S; de Olza, MO; Varga, A; Taylor, M; Schellens, JHM; Wu, HQ; Sun, HY; Silva, AP; Faris, J; Mataraza, J; Cameron, S; Bauer, TM

Naing, A (corresponding author), Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020; 8 (1):

Abstract

Background Spartalizumab is a humanized IgG4 kappa monoclonal antibody that binds programmed death-1 (PD-1) and blocks its interaction with PD-L1 and ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索